Gemini Therapeutics (GMTX) Issues Corporate Update

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/13/2026

1. WDAY
2. AAPL
3. JNJ
4. AMAT
5. META
6. NVDA
7. NRIX
8. SPY
9. OIG
10. BAC

Go back to Gemini Therapeutics (GMTX) Issues Corporate Update

Gemini Therapeutics Provides Corporate Update

February 28, 2022 8:30 AM EST

Remote-First-Company/Mass.--(BUSINESS WIRE)-- Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically-defined age-related macular degeneration (AMD), today provided a corporate update announcing a leadership transition, strategic evaluation and corporate restructuring.

The Board of Directors has appointed Georges Gemayel, Ph.D., the Companys current Executive Chair, as interim President and Chief Executive Officer to succeed Jason Meyenburg, who has transitioned from his roles as President, CEO and Director and will continue to serve as an advisor to the Company.

Additionally, the Company has... More